Longitudinal assessment of disease activity and muscle strength in juvenile dermatomyositis: a multicentre registry study

To define disease activity measures, muscle strength and functional assessments in new-onset juvenile dermatomyositis (JDM) patients, at disease onset and follow up. A registry was set up in 18 hospitals, enrolling patients over 3-years (2015-2018). Clinical assessments were performed at baseline, a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental rheumatology 2024-09
Hauptverfasser: Hortelan Antonio, Darcisio, Carneiro, Beatriz O L, Fernandes, Taciana A P, Elias, Adriana M, Pantoja de Moraes, Ana Julia, Vecchi, Ana Paula, Cavalcanti, Andre, Rabelo, Jr, Carlos N, Magalhaes, Cristina M, Sztajnbok, Flavio R, Carvalho, Luciana M, Paim Marques, Luciana, Terreri, Maria Teresa, Fraga, Melissa M, de Oliveira, Sheila K F, Sacchetti, Silvana B, Appenzeller, Simone, Robazzi, Teresa, Ferriani, Virginia P L, Len, Claudio A, Silva, Clovis A A, Saad-Magalhaes, Claudia
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To define disease activity measures, muscle strength and functional assessments in new-onset juvenile dermatomyositis (JDM) patients, at disease onset and follow up. A registry was set up in 18 hospitals, enrolling patients over 3-years (2015-2018). Clinical assessments were performed at baseline, and at 6, 12, 18 and 24 months after diagnosis. Disease Activity Score (DAS20), skin and musculoskeletal DAS sub-scales; Manual Muscle Test (MMT8); Childhood Myositis Assessment Scale (CMAS); Childhood Health Assessment Questionnaire disability index (CHAQ_DI 0-3) and 10 cm Visual Analog Scale (VAS) for overall wellbeing scores were compared by Poisson Model and Wald post-test for repeated measures. Ninety-six cases, being 61 (64%) females, median age 10 years had JDM diagnosis and 12 (13%) onset calcinosis. Mean ±SD scores at diagnosis and 6 months intervals for DAS20 (0-20) were 7.8±5, 6.3 ±4.8, 5±4, 4.9 ±5 and 0.5 ±2.3; with significant difference from baseline (p
ISSN:0392-856X
1593-098X
1593-098X
DOI:10.55563/clinexprheumatol/yrb7m2